Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Mast Cell Disorders
•
Primary Care
Do you recommend patients try antihistamines such as oral ketotifen that are not approved in the US but are approved in the EU for MCAS if currently available formulations have not been effective?
Related Questions
How do you discuss the overlap of POTS, Ehlers-Danlos and MCAS with patients?
What is your preferred biologic for an asthmatic patient with a T2 low phenotype and who is a smoker?
Do you find that hydroxyzine worsens cognitive symptoms in patients who are already susceptible to cognitive impairment (i.e., schizophrenia, ADHD, dementia)?
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
Do you retest for environmental aeroallergens when patients have relocated within the US between vastly different climates?
When would you favor initiation of mepolizumab versus dupilumab for CRSwNP?
Does splitting the dose of a vaccine during an observed administration affect the efficacy of the vaccine response?
Do you switch from 0.15 mg to 0.3 mg epinephrine at 55lbs or 66lbs?
Should IVIG dosing in patients with autoimmune disease (i.e., dermatomyositis) who become pregnant continue to be based on actual weight at the time of each infusion, or should it be limited to pre-pregnancy weight?
What are your recommendations for managing perivascular dermatitis with eosinophils unresponsive to high-dose antihistamines, a prednisone taper, and topical steroids?
